Pre-made Dostarlimab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Dostarlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-154-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Dostarlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name	Dostarlimab
Target	PDCD1/PD-1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO
Conditions Approved	Endometrial cancer;Solid tumours
Conditions Active	Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer
Conditions Discontinued	na
Development Tech	na